Controlled Clinical TrialtaVNSn = 25

Effect of transcutaneous auricular vagus nerve stimulation on major depressive disorder with peripartum onset: A multicenter, open-label, controlled proof-of-concept clinical trial (DELOS-1)

Deligiannidis KM, Robakis T, Homitsky SC, Ibroci E, King B, Jacob S, Coppola D, Raines S, Alataris K

Journal of Affective Disorders · 2022

Key finding

In 25 women with peripartum-onset MDD, 6 weeks of open-label taVNS yielded 74% response and 61% remission with a mean HAM-D reduction of ~9.7 points and no serious adverse events.

Condition
Depression
Stimulation
taVNS
Evidence tier
Controlled Clinical Trial
Participants
25
View on DOI

Cite this study

Deligiannidis, K. M., Robakis, T., Homitsky, S. C., Ibroci, E., King, B., Jacob, S., Coppola, D., Raines, S., & Alataris, K. (2022). Effect of transcutaneous auricular vagus nerve stimulation on major depressive disorder with peripartum onset: A multicenter, open-label, controlled proof-of-concept clinical trial (DELOS-1). Journal of Affective Disorders, 316, 34-41. https://doi.org/10.1016/j.jad.2022.07.068

Related studies in Depression

Summary by Vagus Research. Always consult the primary source for the authoritative record.

Stay Current with the Research

Join researchers and practitioners exploring the science of vagus nerve stimulation. Receive curated research summaries and evidence updates.

No spam. Unsubscribe at any time. We respect your privacy.